Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.35 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.35 |
| ▸ | LATS1 | O95835 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | GCGR | P47871 | 1/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21899492 | 1.00 | GSK3B (0.39) | GSK3BCDC7GRIA1GRIA2GRIA3 | |
| SCHEMBL21853840 | 0.91 | GSK3B (0.38) | GSK3BGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL22551027 | 0.91 | GSK3B (0.38) | GSK3BGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL20012467 | 0.86 | GSK3B (0.51) | GSK3BGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL20011889 | 0.86 | GSK3B (0.51) | GSK3BGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL19995892 | 0.84 | GSK3B (0.40) | GSK3BCDC7GRIA1GRIA2GRIA3 | |
| SCHEMBL20012468 | 0.84 | GSK3B (0.40) | GSK3BCDC7GRIA1GRIA2GRIA3 | |
| SCHEMBL22563193 | 0.84 | GSK3B (0.40) | GSK3BCDC7GRIA1GRIA2GRIA3 | |
| SCHEMBL21853878 | 0.82 | GSK3B (0.38) | GSK3BGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL19995235 | 0.82 | GSK3B (0.38) | GSK3BGRIA1GRIA2GRIA3GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110036006-B | Preparation and use of pyrimidinone derivatives | 癌症研究科技有限公司 | 2022-12-13 | — | — | CN | claimed |
| US-10919896-B2 | Preparation and uses of pyrimidinone derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-02-16 | — | — | US | claimed |
| EP-3515903-B1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES | CANCER RESEARCH TECH LTD (GB) | 2020-10-21 | — | — | EP | claimed |
| US-20200123157-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. | 2020-04-23 | — | — | US | claimed |
| CN-110036006-B | Preparation and use of pyrimidinone derivatives | 癌症研究科技有限公司 | 2022-12-13 | — | — | CN | disclosed |
| US-10919896-B2 | Preparation and uses of pyrimidinone derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-02-16 | — | — | US | disclosed |
| US-10919896-B2 | Preparation and uses of pyrimidinone derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-02-16 | — | — | US | disclosed |
| EP-3515903-B1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES | CANCER RESEARCH TECH LTD (GB) | 2020-10-21 | — | — | EP | disclosed |
| EP-3515903-B1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES | CANCER RESEARCH TECH LTD (GB) | 2020-10-21 | — | — | EP | disclosed |
| US-20200123157-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. | 2020-04-23 | — | — | US | disclosed |
| US-20200123157-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. | 2020-04-23 | — | — | US | disclosed |
| WO-2018055402-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919896-B2 | Preparation and uses of pyrimidinone derivatives | CDC7, CDK7, CDK17 | GSK3B 597/4885CDC7 1/4885GRIA1 2503/4885 |
| US-20200123157-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE | CDC7, CDK7, CDK17 | GSK3B 600/4885CDC7 1/4885GRIA1 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.